Xiaoyi Chong

66PUBLICATIONS
252CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsMechanobiologyPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (66)

|Sep 24, 2026
First-Line Retlirafusp Alfa Plus Chemotherapy for Human Epidermal Growth Factor Receptor 2-Negative Gastric or Gastroesophageal Junction Adenocarcinoma: A Randomized, Double-Blind, Phase III Study (RELIGHT).

|Sep 05, 2026
Efficacy and Safety of DVDMS-Photodynamic Therapy for Dysphagia in Advanced Esophageal Cancer: A Phase II Clinical Trial.

|Jun 04, 2026
Guanylyl Cyclase 2C-Targeted Chimeric Antigen Receptor T-Cell Therapy in Patients With Metastatic Colorectal Cancer.

|Mar 12, 2026
Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial.

Zhi Peng, Yanqiao Zhang, Huiting Xu

|Feb 02, 2026
Identification of factors conferring resistance to trastuzumab deruxtecan in advanced gastric cancer: a translational study from the single-arm, phase II, DESTINY-Gastric06 trial.

Bohan Zhang, Lei Zhang, Cheng Liu

|Dec 29, 2025
Surufatinib combined with sintilimab and IBI310 for the treatment of high-grade advanced-neuroendocrine neoplasms: A single arm, open-label, single-center, phase II study.

Panpan Zhang, Miao Zhang, Yakun Wang

Pageof 11

Frequent Collaborators

7 joint publications

Jian Li

4 joint publications

Ruihua Xu

4 joint publications

Panpan Zhang

4 joint publications

Jun Zhang